1
|
Frydryk Benitez DN, Palmieri MA, Langle YV, Monti Hughes A, Pozzi ECC, Thorp SI, Garabalino MA, Curotto P, Ramos PS, Paparella ML, Polti L, Eiján A, Schwint AE, Trivillin VA. Therapeutic Efficacy, Radiotoxicity and Abscopal Effect of BNCT at the RA-3 Nuclear Reactor Employing Oligo-Fucoidan and Glutamine as Adjuvants in an Ectopic Colon Cancer Model in Rats. Life (Basel) 2023; 13:1538. [PMID: 37511913 PMCID: PMC10381875 DOI: 10.3390/life13071538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 06/16/2023] [Accepted: 07/06/2023] [Indexed: 07/30/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is based on the preferential uptake of 10B compounds by tumors, followed by neutron irradiation. The aim of this study was to assess, in an ectopic colon cancer model, the therapeutic efficacy, radiotoxicity, abscopal effect and systemic immune response associated with (BPA/Borophenylalanine+GB-10/Decahydrodecaborate)-BNCT (Comb-BNCT) alone or in combination with Oligo-Fucoidan (O-Fuco) or Glutamine (GLN), compared to the "standard" BPA-BNCT protocol usually employed in clinical trials. All treatments were carried out at the RA-3 nuclear reactor. Boron biodistribution studies showed therapeutic values above 20 ppm 10B in tumors. At 7 weeks post-treatment, the ratio of tumor volume post-/pre-BNCT was significantly smaller for all BNCT groups vs. SHAM (p < 0.05). The parameter "incidence of tumors that underwent a reduction to ≤50% of initial tumor volume" exhibited values of 62% for Comb-BNCT alone, 82% for Comb-BNCT+GLN, 73% for Comb-BNCT+O-Fuco and only 30% for BPA-BNCT. For BPA-BNCT, the incidence of severe dermatitis was 100%, whereas it was significantly below 70% (p ≤ 0.05) for Comb-BNCT, Comb-BNCT+O-Fuco and Comb-BNCT+GLN. Considering tumors outside the treatment area, 77% of Comb-BNCT animals had a tumor volume lower than 50 mm3 vs. 30% for SHAM (p ≤ 0.005), suggesting an abscopal effect of Comb-BNCT. Inhibition of metastatic spread to lymph nodes was observed in all Comb-BNCT groups. Considering systemic aspects, CD8+ was elevated for Comb-BNCT+GLN vs. SHAM (p ≤ 0.01), and NK was elevated for Comb-BNCT vs. SHAM (p ≤ 0.05). Comb-BNCT improved therapeutic efficacy and reduced radiotoxicity compared to BPA-BNCT and induced an immune response and an abscopal effect.
Collapse
Affiliation(s)
- Debora N Frydryk Benitez
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Av. Int. Güiraldes 2160, 4 Piso, Pab. II, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina
| | - Yanina V Langle
- Facultad de Medicina, Instituto de Oncología Ángel H. Roffo (IOAHR), Universidad de Buenos Aires, Av. S. Martín 5481, Área de Investigación, Ciudad Autónoma de Buenos Aires C1417DTB, Argentina
| | - Andrea Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Emiliano C C Pozzi
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
| | - Silvia I Thorp
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
| | - Marcela A Garabalino
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
| | - Paula Curotto
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
| | - Paula S Ramos
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
| | - María L Paparella
- Facultad Odontología, Universidad de Buenos Aires (UBA), M.T. de Alvear 2142, Ciudad Autónoma de Buenos Aires C1122AAH, Argentina
| | - Lucas Polti
- Facultad Odontología, Universidad de Buenos Aires (UBA), M.T. de Alvear 2142, Ciudad Autónoma de Buenos Aires C1122AAH, Argentina
| | - Ana Eiján
- Facultad de Medicina, Instituto de Oncología Ángel H. Roffo (IOAHR), Universidad de Buenos Aires, Av. S. Martín 5481, Área de Investigación, Ciudad Autónoma de Buenos Aires C1417DTB, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Amanda E Schwint
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Verónica A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), Av. General Paz 1499, San Martin, Buenos Aires C1650KNA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| |
Collapse
|
2
|
Olaiz N, Monti Hughes A, Pozzi ECC, Thorp S, Curotto P, Trivillin VA, Ramos PS, Palmieri MA, Marshall G, Schwint AE, Garabalino MA. Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer. Cells 2023; 12:cells12091241. [PMID: 37174642 PMCID: PMC10177359 DOI: 10.3390/cells12091241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/17/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) combines preferential tumor uptake of 10B compounds and neutron irradiation. Electroporation induces an increase in the permeability of the cell membrane. We previously demonstrated the optimization of boron biodistribution and microdistribution employing electroporation (EP) and decahydrodecaborate (GB-10) as the boron carrier in a hamster cheek pouch oral cancer model. The aim of the present study was to evaluate if EP could improve tumor control without enhancing the radiotoxicity of BNCT in vivo mediated by GB-10 with EP 10 min after GB-10 administration. Following cancerization, tumor-bearing hamster cheek pouches were treated with GB-10/BNCT or GB-10/BNCT + EP. Irradiations were carried out at the RA-3 Reactor. The tumor response and degree of mucositis in precancerous tissue surrounding tumors were evaluated for one month post-BNCT. The overall tumor response (partial remission (PR) + complete remission (CR)) increased significantly for protocol GB-10/BNCT + EP (92%) vs. GB-10/BNCT (48%). A statistically significant increase in the CR was observed for protocol GB-10/BNCT + EP (46%) vs. GB-10/BNCT (6%). For both protocols, the radiotoxicity (mucositis) was reversible and slight/moderate. Based on these results, we concluded that electroporation improved the therapeutic efficacy of GB-10/BNCT in vivo in the hamster cheek pouch oral cancer model without increasing the radiotoxicity.
Collapse
Affiliation(s)
- Nahuel Olaiz
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Andrea Monti Hughes
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Silvia Thorp
- Sub-Gerencia Instrumentación y Control, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Verónica A Trivillin
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Paula S Ramos
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón II, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
| | - Guillermo Marshall
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Amanda E Schwint
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Marcela A Garabalino
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| |
Collapse
|
3
|
Monti Hughes A, Goldfinger JA, Palmieri MA, Ramos P, Santa Cruz IS, De Leo L, Garabalino MA, Thorp SI, Curotto P, Pozzi ECC, Kawai K, Sato S, Itoiz ME, Trivillin VA, Guidobono JS, Nakamura H, Schwint AE. Boron Neutron Capture Therapy (BNCT) Mediated by Maleimide-Functionalized Closo-Dodecaborate Albumin Conjugates (MID:BSA) for Oral Cancer: Biodistribution Studies and In Vivo BNCT in the Hamster Cheek Pouch Oral Cancer Model. Life (Basel) 2022; 12:life12071082. [PMID: 35888170 PMCID: PMC9323568 DOI: 10.3390/life12071082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/11/2022] [Accepted: 07/14/2022] [Indexed: 12/12/2022]
Abstract
Background: BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although p-boronophenylalanine (BPA) has been clinically used, new boron compounds are needed for the advancement of BNCT. Based on previous studies in colon tumor-bearing mice, in this study, we evaluated MID:BSA (maleimide-functionalized closo-dodecaborate conjugated to bovine serum albumin) biodistribution and MID:BSA/BNCT therapeutic effect on tumors and associated radiotoxicity in the hamster cheek pouch oral cancer model. Methods: Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue. Results: MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity. Conclusions: MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
- Correspondence: or ; Tel.: +54-9-11-41689832 or +54-11-6772-7927
| | - Jessica A. Goldfinger
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Mónica A. Palmieri
- Biodiversity and Experimental Biology Department, School of Exact and Natural Sciences, University of Buenos Aires, Av. Int. Güiraldes 2160, 4° piso, Pab. II, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina;
| | - Paula Ramos
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Iara S. Santa Cruz
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Luciana De Leo
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Marcela A. Garabalino
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
| | - Silvia I. Thorp
- Department of Instrumentation and Control, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina;
| | - Paula Curotto
- Department of Research and Production Reactors, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina; (P.C.); (E.C.C.P.)
| | - Emiliano C. C. Pozzi
- Department of Research and Production Reactors, National Atomic Energy Commission, Presbítero Juan González y Aragon, 15, Ezeiza, Buenos Aires B1802AYA, Argentina; (P.C.); (E.C.C.P.)
| | - Kazuki Kawai
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
| | - Shinichi Sato
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
| | - María E. Itoiz
- Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, M.T. de Alvear 2142, Ciudad Autónoma de Buenos Aires C1122AAH, Argentina;
| | - Verónica A. Trivillin
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| | - Juan S. Guidobono
- Buenos Aires Institute of Ecology, Genetics and Evolution (IEGEBA), CONICET, UBA, Intendente Güiraldes 2160, Ciudad Universitaria, Ciudad Autónoma de Buenos Aires C1428EGA, Argentina;
| | - Hiroyuki Nakamura
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8503, Japan; (K.K.); (S.S.); (H.N.)
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
| | - Amanda E. Schwint
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, San Martin, Buenos Aires B1650KNA, Argentina; (J.A.G.); (P.R.); (I.S.S.C.); (L.D.L.); (M.A.G.); (V.A.T.); or (A.E.S.)
- National Scientific and Technical Research Council (CONICET), Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
| |
Collapse
|
4
|
Trivillin VA, Langle YV, Palmieri MA, Pozzi ECC, Thorp SI, Benitez Frydryk DN, Garabalino MA, Monti Hughes A, Curotto PM, Colombo LL, Santa Cruz IS, Ramos PS, Itoiz ME, Argüelles C, Eiján AM, Schwint AE. Evaluation of local, regional and abscopal effects of Boron Neutron Capture Therapy (BNCT) combined with immunotherapy in an ectopic colon cancer model. Br J Radiol 2021; 94:20210593. [PMID: 34520668 DOI: 10.1259/bjr.20210593] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
OBJECTIVE The aim of the present study was to evaluate the local and regional therapeutic efficacy and abscopal effect of BNCT mediated by boronophenyl-alanine, combined with Bacillus Calmette-Guerin (BCG) as an immunotherapy agent in this model. METHODS The local effect of treatment was evaluated in terms of tumor response in the irradiated tumor-bearing right hind flank. Metastatic spread to tumor-draining lymph nodes was analyzed as an indicator of regional effect. The abscopal effect of treatment was assessed as tumor growth inhibition in the contralateral (non-irradiated) left hind flank inoculated with tumor cells 2 weeks post-irradiation. The experimental groups BNCT, BNCT + BCG, BCG, Beam only (BO), BO +BCG, SHAM (tumor-bearing, no treatment, same manipulation) were studied. RESULTS BNCT and BNCT + BCG induced a highly significant local anti-tumor response, whereas BCG alone induced a weak local effect. BCG and BNCT + BCG induced a significant abscopal effect in the contralateral non-irradiated leg. The BNCT + BCG group showed significantly less metastatic spread to tumor-draining lymph nodes vs SHAM and vs BO. CONCLUSION This study suggests that BNCT + BCG-immunotherapy would induce local, regional and abscopal effects in tumor-bearing animals. BNCT would be the main effector of the local anti-tumor effect whereas BCG would be the main effector of the abscopal effect. ADVANCES IN KNOWLEDGE Although the local effect of BNCT has been widely evidenced, this is the first study to show the local, regional and abscopal effects of BNCT combined with immunotherapy, contributing to comprehensive cancer treatment with combined therapies.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Yanina V Langle
- Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo, Área Investigación, Buenos Aires, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina
| | | | - Silvia I Thorp
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | | | | | - Andrea Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Paula M Curotto
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Lucas L Colombo
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.,Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo, Área Investigación, Buenos Aires, Argentina
| | - Iara S Santa Cruz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Paula S Ramos
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - María E Itoiz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Facultad de Odontología, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina
| | - Claudia Argüelles
- Instituto Nacional de Producción de Biológicos, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina
| | - Ana M Eiján
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.,Universidad de Buenos Aires, Instituto de Oncología Ángel H. Roffo, Área Investigación, Buenos Aires, Argentina
| | - Amanda E Schwint
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
5
|
Schwint AE, Monti Hughes A, Garabalino MA, Santa Cruz GA, González SJ, Longhino J, Provenzano L, Oña P, Rao M, Cantarelli MDLÁ, Leiras A, Olivera MS, Trivillin VA, Alessandrini P, Brollo F, Boggio E, Costa H, Ventimiglia R, Binia S, Pozzi ECC, Nievas SI, Santa Cruz IS. Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between Translational and Clinical Studies. Biology (Basel) 2020; 9:biology9100327. [PMID: 33036386 PMCID: PMC7599538 DOI: 10.3390/biology9100327] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/01/2020] [Accepted: 10/05/2020] [Indexed: 01/08/2023]
Abstract
Simple Summary Boron Neutron Capture Therapy (BNCT) is a treatment for cancer based on the selective accumulation in tumor of boron compounds, followed by external irradiation with neutrons. The interaction between boron-10 and a neutron gives rise to very energetic particles that travel only a very short distance (approximately the diameter of a cell) and are lethal for the cell. In this way, BNCT damages tumor tissue selectively while preserving normal tissue. BNCT has proved effective to treat certain tumors in clinical trials worldwide, with room for improvement. Our group has worked on animal models to improve the efficacy of BNCT, in particular for head and neck cancer. Herein we performed clinical veterinary BNCT studies in five terminal dog patients with head and neck cancer with no other therapeutic option. In all cases we observed partial tumor response, clinical benefit, and extension of estimated survival time at recruitment with excellent quality of life. Toxicity associated to the treatment was mild/moderate and reversible. These studies contribute towards preparation for clinical BNCT trials for head and neck cancer in Argentina and suggest a potential role for BNCT in veterinary medicine. Abstract Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3–5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.
Collapse
Affiliation(s)
- Amanda E. Schwint
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
- Correspondence: ; Tel.: +54-911-6496-7168
| | - Andrea Monti Hughes
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Marcela A. Garabalino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Gustavo A. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Sara J. González
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Juan Longhino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Lucas Provenzano
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paulina Oña
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Monica Rao
- Hospital Veterinario, Gobernador M. Ugarte 2152, Olivos, B1636BWT, Provincia Buenos Aires, Argentina;
| | | | - Andrea Leiras
- Independent Veterinarian, Huilqui 12356, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - María Silvina Olivera
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Verónica A. Trivillin
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paula Alessandrini
- Independent Veterinarian, Lonquimay 3817, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - Fabricio Brollo
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Esteban Boggio
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Hernan Costa
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Romina Ventimiglia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Sergio Binia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Emiliano C. C. Pozzi
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Susana I. Nievas
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Iara S. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| |
Collapse
|
6
|
Santa Cruz IS, Garabalino MA, Trivillin VA, Itoiz ME, Pozzi ECC, Thorp S, Curotto P, Guidobono JS, Heber EM, Nigg DW, Schwint AE, Monti Hughes A. Optimization of the classical oral cancerization protocol in hamster to study oral cancer therapy. Oral Dis 2020; 26:1175-1184. [PMID: 32297432 DOI: 10.1111/odi.13358] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 04/01/2020] [Accepted: 04/03/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE(S) The hamster carcinogenesis model recapitulates oral oncogenesis. Dimethylbenz[a]anthracene (DMBA) cancerization induces early severe mucositis, affecting animal's welfare and causing tissue loss and pouch shortening. "Short" pouches cannot be everted for local irradiation for boron neutron capture therapy (BNCT). Our aim was to optimize the DMBA classical cancerization protocol to avoid severe mucositis, without affecting tumor development. We evaluated BNCT in animals cancerized with this novel protocol. MATERIALS AND METHODS We studied: Classical cancerization protocol (24 applications) and Classical with two interruptions (completed at the end of the cancerization protocol). BNCT mediated by boronophenylalanine (BPA) was performed in both groups. RESULTS The twice-interrupted group exhibited a significantly lower percentage of animals with severe mucositis versus the non-interrupted group (17% versus 71%) and a significantly higher incidence of long pouches (100% versus 53%). Tumor development and the histologic characteristics of tumor and precancerous tissue were not affected by the interruptions. For both groups, overall tumor response was more than 80%, with a similar incidence of BNCT-induced severe mucositis. CONCLUSION(S) The twice-interrupted protocol reduced severe mucositis during cancerization without affecting tumor development. This favored the animal's welfare and reduced the number of animals to be cancerized for our studies, without affecting BNCT response.
Collapse
Affiliation(s)
- Iara S Santa Cruz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | | | - Verónica A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - María E Itoiz
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Facultad de Odontología, UBA, Buenos Aires, Argentina
| | | | - Silvia Thorp
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Paula Curotto
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - Juan S Guidobono
- Instituto de Ecología, Genética y Evolución de Buenos Aires (IEGEBA), CONICET, UBA, Buenos Aires, Argentina
| | - Elisa M Heber
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory USA, Idaho Falls, ID, USA
| | - Amanda E Schwint
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| |
Collapse
|
7
|
Garabalino MA, Olaiz N, Portu A, Saint Martin G, Thorp SI, Pozzi ECC, Curotto P, Itoiz ME, Monti Hughes A, Colombo LL, Nigg DW, Trivillin VA, Marshall G, Schwint AE. Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model. Radiat Environ Biophys 2019; 58:455-467. [PMID: 31123853 DOI: 10.1007/s00411-019-00796-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Accepted: 05/07/2019] [Indexed: 05/17/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer binary therapy modality that utilizes the nuclear capture reaction of thermal neutrons by boron-10 resulting in a localized release of high- and low-linear energy transfer (LET) radiation. Electrochemotherapy (ECT) is based on electroporation (EP) that induces opening of pores in cell membranes, allowing the entry of compounds. Because EP is applied locally to a tumor, the compound is incorporated preferentially by tumor cells. Based on the knowledge that the therapeutic success of BNCT depends centrally on the boron content in tumor and normal tissues and that EP has proven to be an excellent facilitator of tumor biodistribution of an anti-tumor agent, the aim of this study was to evaluate if EP can optimize the delivery of boronated compounds. We performed biodistribution studies and qualitative microdistribution analyses of boron employing the boron compound sodium decahydrodecaborate (GB-10) + EP in the hamster cheek pouch oral cancer model. Syrian hamsters with chemically induced exophytic squamous cell carcinomas were used. A typical EP treatment was applied to each tumor, varying the moment of application with respect to the administration of GB-10 (early or late). The results of this study showed a significant increase in the absolute and relative tumor boron concentration and optimization of the qualitative microdistribution of boron by the use of early EP + GB-10 versus GB-10 without EP. This strategy could be a tool to improve the therapeutic efficacy of BNCT/GB-10 in vivo.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina.
| | - Nahuel Olaiz
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Agustina Portu
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Gisela Saint Martin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Silvia I Thorp
- Sub-gerencia Instrumentación y Control, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - María E Itoiz
- Departamento de Anatomía Patología, Facultad de Odontología, Universidad de Buenos Aires, Marcelo T. de Alvear 2142, C1122AAH, Ciudad Autónoma De Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Lucas L Colombo
- Instituto de Oncología Angel H. Roffo, Avenida San Martin 5481, C1417DTB, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory, 2525 Fremont Ave, Idaho Falls, ID, 83402, USA
| | - Verónica A Trivillin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Guillermo Marshall
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| |
Collapse
|
8
|
Schwint AE, Garabalino MA, Hughes AM, Pozzi ECC, Heber EM, Palmieri MA, Trivillin VA. Teachings of our translational studies on boron neutron capture therapy (BNCT): thinking “outside the box”. ACTA ACUST UNITED AC 2019. [DOI: 10.21037/tro.2019.05.03] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
9
|
Trivillin VA, Pozzi ECC, Colombo LL, Thorp SI, Garabalino MA, Monti Hughes A, González SJ, Farías RO, Curotto P, Santa Cruz GA, Carando DG, Schwint AE. Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer. Radiat Environ Biophys 2017; 56:365-375. [PMID: 28791476 DOI: 10.1007/s00411-017-0704-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 07/29/2017] [Indexed: 06/07/2023]
Abstract
The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 × 106 DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue. The remaining group of 14 tumor-bearing rats were left untreated and used as control. Two weeks post-BNCT, 1 × 106 DHD/K12/TRb cells were injected subcutaneously in the contralateral left hind flank of each of the 26 BDIX rats. Tumor volume in both legs was measured weekly for 7 weeks to determine response to BNCT in the right leg and to assess a potential influence of BNCT in the right leg on tumor development in the left leg. Within the BNCT group, a statistically significant reduction was observed in contralateral left tumor volume in animals whose right leg tumor responded to BNCT (post-treatment/pre-treatment tumor volume <1) versus animals who failed to respond (post/pre ≥1), i.e., 13 ± 15 vs 271 ± 128 mm3. In addition, a statistically significant reduction in contralateral left leg tumor volume was observed in BNCT-responsive animals (post/pre <1) vs untreated animals, i.e., 13 ± 15 vs 254 ± 251 mm3. The present study performed in a simple animal model provides proof of principle that the positive response of a tumor to BNCT is capable of inducing an abscopal effect.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Department of Research and Production Reactors, Centro Atómico Ezeiza, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Lucas L Colombo
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- Instituto de Oncología Ángel H. Roffo, Ciudad Autónoma de Buenos Aires, Argentina
| | - Silvia I Thorp
- Department of Instrumentation and Control, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Marcela A Garabalino
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Sara J González
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- Department of Instrumentation and Control, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Rubén O Farías
- Department of Instrumentation and Control, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Paula Curotto
- Department of Research and Production Reactors, Centro Atómico Ezeiza, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Gustavo A Santa Cruz
- Department of Boron Neutron Capture Therapy, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Daniel G Carando
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- Faculty of Exact and Natural Sciences, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Amanda E Schwint
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina.
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
10
|
Monti Hughes A, Longhino J, Boggio E, Medina VA, Martinel Lamas DJ, Garabalino MA, Heber EM, Pozzi ECC, Itoiz ME, Aromando RF, Nigg DW, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new "B2" configuration of the RA-6 nuclear reactor. Radiat Environ Biophys 2017; 56:377-387. [PMID: 28871389 DOI: 10.1007/s00411-017-0710-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 08/22/2017] [Indexed: 06/07/2023]
Abstract
Boron neutron capture therapy (BNCT) is based on selective accumulation of B-10 carriers in tumor followed by neutron irradiation. We demonstrated, in 2001, the therapeutic effect of BNCT mediated by BPA (boronophenylalanine) in the hamster cheek pouch model of oral cancer, at the RA-6 nuclear reactor. Between 2007 and 2011, the RA-6 was upgraded, leading to an improvement in the performance of the BNCT beam (B2 configuration). Our aim was to evaluate BPA-BNCT radiotoxicity and tumor control in the hamster cheek pouch model of oral cancer at the new "B2" configuration. We also evaluated, for the first time in the oral cancer model, the radioprotective effect of histamine against mucositis in precancerous tissue as the dose-limiting tissue. Cancerized pouches were exposed to: BPA-BNCT; BPA-BNCT + histamine; BO: Beam only; BO + histamine; CONTROL: cancerized, no-treatment. BNCT induced severe mucositis, with an incidence that was slightly higher than in "B1" experiments (86 vs 67%, respectively). BO induced low/moderate mucositis. Histamine slightly reduced the incidence of severe mucositis induced by BPA-BNCT (75 vs 86%) and prevented mucositis altogether in BO animals. Tumor overall response was significantly higher in BNCT (94-96%) than in control (16%) and BO groups (9-38%), and did not differ significantly from the "B1" results (91%). Histamine did not compromise BNCT therapeutic efficacy. BNCT radiotoxicity and therapeutic effect at the B1 and B2 configurations of RA-6 were consistent. Histamine slightly reduced mucositis in precancerous tissue even in this overly aggressive oral cancer model, without compromising tumor control.
Collapse
Affiliation(s)
- Andrea Monti Hughes
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina.
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina.
| | - Juan Longhino
- Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, San Carlos de Bariloche, Province Rio Negro, Argentina
| | - Esteban Boggio
- Department of Nuclear Engineering, Bariloche Atomic Center, CNEA, San Carlos de Bariloche, Province Rio Negro, Argentina
| | - Vanina A Medina
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
- Laboratory of Tumoral Biology and Inflammation, School of Medical Sciences, Institute for Biomedical Research (BIOMED CONICET-UCA), Pontifical Catholic University of Argentina (UCA), Ciudad Autonoma de Buenos Aires, Argentina
| | - Diego J Martinel Lamas
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
- Laboratory of Tumoral Biology and Inflammation, School of Medical Sciences, Institute for Biomedical Research (BIOMED CONICET-UCA), Pontifical Catholic University of Argentina (UCA), Ciudad Autonoma de Buenos Aires, Argentina
| | - Marcela A Garabalino
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
| | - Elisa M Heber
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
| | - María E Itoiz
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
- Department of Oral Pathology, Faculty of Dentistry, UBA, Ciudad Autonoma de Buenos Aires, Argentina
| | - Romina F Aromando
- Department of Oral Pathology, Faculty of Dentistry, UBA, Ciudad Autonoma de Buenos Aires, Argentina
| | | | - Verónica A Trivillin
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
| | - Amanda E Schwint
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Province Buenos Aires, Argentina
- National Research Council (CONICET), Ciudad Autonoma de Buenos Aires, Argentina
| |
Collapse
|
11
|
González SJ, Pozzi ECC, Monti Hughes A, Provenzano L, Koivunoro H, Carando DG, Thorp SI, Casal MR, Bortolussi S, Trivillin VA, Garabalino MA, Curotto P, Heber EM, Santa Cruz GA, Kankaanranta L, Joensuu H, Schwint AE. Photon iso-effective dose for cancer treatment with mixed field radiation based on dose–response assessment from human and an animal model: clinical application to boron neutron capture therapy for head and neck cancer. ACTA ACUST UNITED AC 2017; 62:7938-7958. [DOI: 10.1088/1361-6560/aa8986] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
12
|
Trivillin VA, Bruno LJ, Gatti DA, Stur M, Garabalino MA, Hughes AM, Castillo J, Pozzi ECC, Wentzeis L, Scolari H, Schwint AE, Feldman S. Boron neutron capture synovectomy (BNCS) as a potential therapy for rheumatoid arthritis: radiobiological studies at RA-1 Nuclear Reactor in a model of antigen-induced arthritis in rabbits. Radiat Environ Biophys 2016; 55:467-475. [PMID: 27568399 DOI: 10.1007/s00411-016-0664-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Accepted: 08/17/2016] [Indexed: 06/06/2023]
Abstract
Rheumatoid arthritis is a chronic autoimmune pathology characterized by the proliferation and inflammation of the synovium. Boron neutron capture synovectomy (BNCS), a binary treatment modality that combines the preferential incorporation of boron carriers to target tissue and neutron irradiation, was proposed to treat the pathological synovium in arthritis. In a previous biodistribution study, we showed the incorporation of therapeutically useful boron concentrations to the pathological synovium in a model of antigen-induced arthritis (AIA) in rabbits, employing two boron compounds approved for their use in humans, i.e., decahydrodecaborate (GB-10) and boronophenylalanine (BPA). The aim of the present study was to perform low-dose BNCS studies at the RA-1 Nuclear Reactor in the same model. Neutron irradiation was performed post intra-articular administration of BPA or GB-10 to deliver 2.4 or 3.9 Gy, respectively, to synovium (BNCS-AIA). AIA and healthy animals (no AIA) were used as controls. The animals were followed clinically for 2 months. At that time, biochemical, magnetic resonance imaging (MRI) and histological studies were performed. BNCS-AIA animals did not show any toxic effects, swelling or pain on palpation. In BNCS-AIA, the post-treatment levels of TNF-α decreased in four of six rabbits and IFN-γ levels decreased in five of six rabbits. In all cases, MRI images of the knee joint in BNCS-AIA resembled those of no AIA, with no necrosis or periarticular effusion. Synovial membranes of BNCS-AIA were histologically similar to no AIA. BPA-BNCS and GB-10-BNCS, even at low doses, would be therapeutically useful for the local treatment of rheumatoid arthritis.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina.
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina.
| | - Leandro J Bruno
- LABOATEM (Laboratorio de Biología Osteoarticular, Ingeniería Tisular y Terapias Emergentes), Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
| | - David A Gatti
- LABOATEM (Laboratorio de Biología Osteoarticular, Ingeniería Tisular y Terapias Emergentes), Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
| | - Mariela Stur
- Cátedra de Diagnóstico por Imágenes, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
| | - Marcela A Garabalino
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina
| | - Jorge Castillo
- Department of Reactors, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Department of Research and Production Reactors, Comisión Nacional de Energía Atómica (CNEA), Presbítero Juan González y Aragon 15, B1802AYA, Ezeiza, Province Buenos Aires, Argentina
| | - Luis Wentzeis
- Department of Reactors, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina
| | - Hugo Scolari
- Department of Reactors, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina
| | - Amanda E Schwint
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martín, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Sara Feldman
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- LABOATEM (Laboratorio de Biología Osteoarticular, Ingeniería Tisular y Terapias Emergentes), Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
| |
Collapse
|
13
|
Farías RO, Garabalino MA, Ferraris S, Santa María J, Rovati O, Lange F, Trivillin VA, Monti Hughes A, Pozzi ECC, Thorp SI, Curotto P, Miller ME, Santa Cruz GA, Bortolussi S, Altieri S, Portu AM, Saint Martin G, Schwint AE, González SJ. Toward a clinical application of ex situ boron neutron capture therapy for lung tumors at the RA-3 reactor in Argentina. Med Phys 2016; 42:4161-73. [PMID: 26133616 DOI: 10.1118/1.4922158] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Many types of lung tumors have a very poor prognosis due to their spread in the whole organ volume. The fact that boron neutron capture therapy (BNCT) would allow for selective targeting of all the nodules regardless of their position, prompted a preclinical feasibility study of ex situ BNCT at the thermal neutron facility of RA-3 reactor in the province of Buenos Aires, Argentina. (l)-4p-dihydroxy-borylphenylalanine fructose complex (BPA-F) biodistribution studies in an adult sheep model and computational dosimetry for a human explanted lung were performed to evaluate the feasibility and the therapeutic potential of ex situ BNCT. METHODS Two kinds of boron biodistribution studies were carried out in the healthy sheep: a set of pharmacokinetic studies without lung excision, and a set that consisted of evaluation of boron concentration in the explanted and perfused lung. In order to assess the feasibility of the clinical application of ex situ BNCT at RA-3, a case of multiple lung metastases was analyzed. A detailed computational representation of the geometry of the lung was built based on a real collapsed human lung. Dosimetric calculations and dose limiting considerations were based on the experimental results from the adult sheep, and on the most suitable information published in the literature. In addition, a workable treatment plan was considered to assess the clinical application in a realistic scenario. RESULTS Concentration-time profiles for the normal sheep showed that the boron kinetics in blood, lung, and skin would adequately represent the boron behavior and absolute uptake expected in human tissues. Results strongly suggest that the distribution of the boron compound is spatially homogeneous in the lung. A constant lung-to-blood ratio of 1.3 ± 0.1 was observed from 80 min after the end of BPA-F infusion. The fact that this ratio remains constant during time would allow the blood boron concentration to be used as a surrogate and indirect quantification of the estimated value in the explanted healthy lung. The proposed preclinical animal model allowed for the study of the explanted lung. As expected, the boron concentration values fell as a result of the application of the preservation protocol required to preserve the lung function. The distribution of the boron concentration retention factor was obtained for healthy lung, with a mean value of 0.46 ± 0.14 consistent with that reported for metastatic colon carcinoma model in rat perfused lung. Considering the human lung model and suitable tumor control probability for lung cancer, a promising average fraction of controlled lesions higher than 85% was obtained even for a low tumor-to-normal boron concentration ratio of 2. CONCLUSIONS This work reports for the first time data supporting the validity of the ovine model as an adequate human surrogate in terms of boron kinetics and uptake in clinically relevant tissues. Collectively, the results and analysis presented would strongly suggest that ex situ whole lung BNCT irradiation is a feasible and highly promising technique that could greatly contribute to the treatment of metastatic lung disease in those patients without extrapulmonary spread, increasing not only the expected overall survival but also the resulting quality of life.
Collapse
Affiliation(s)
- R O Farías
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1033, Argentina
| | - M A Garabalino
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - S Ferraris
- CIDME, Universidad Maimónides, Buenos Aires 1405, Argentina
| | - J Santa María
- CIDME, Universidad Maimónides, Buenos Aires 1405, Argentina
| | - O Rovati
- CIDME, Universidad Maimónides, Buenos Aires 1405, Argentina
| | - F Lange
- CIDME, Universidad Maimónides, Buenos Aires 1405, Argentina
| | - V A Trivillin
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1033, Argentina
| | - A Monti Hughes
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - E C C Pozzi
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - S I Thorp
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - P Curotto
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - M E Miller
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - G A Santa Cruz
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - S Bortolussi
- Istituto Nazionale di Fisica Nucleare, Sezione di Pavia 27100, Italy
| | - S Altieri
- Istituto Nazionale di Fisica Nucleare, Sezione di Pavia 27100, Italy and Dipartimento di Fisica, Università di Pavia, Pavia 27100, Italy
| | - A M Portu
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1033, Argentina
| | - G Saint Martin
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina
| | - A E Schwint
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1033, Argentina
| | - S J González
- Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1033, Argentina
| |
Collapse
|
14
|
Monti Hughes A, Pozzi ECC, Thorp SI, Curotto P, Medina VA, Martinel Lamas DJ, Rivera ES, Garabalino MA, Farías RO, Gonzalez SJ, Heber EM, Itoiz ME, Aromando RF, Nigg DW, Trivillin VA, Schwint AE. Histamine reduces boron neutron capture therapy-induced mucositis in an oral precancer model. Oral Dis 2015; 21:770-7. [DOI: 10.1111/odi.12346] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 04/10/2014] [Accepted: 04/19/2015] [Indexed: 02/04/2023]
Affiliation(s)
- A Monti Hughes
- Department of Radiobiology; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
| | - ECC Pozzi
- Department of Research and Production Reactors; National Atomic Energy Commission; Ezeiza Province Buenos Aires Argentina
| | - SI Thorp
- Department of Instrumentation and Control; National Atomic Energy Commission; Ezeiza Province Buenos Aires Argentina
| | - P Curotto
- Department of Research and Production Reactors; National Atomic Energy Commission; Ezeiza Province Buenos Aires Argentina
| | - VA Medina
- Radioisotopes Laboratory; School of Pharmacy and Biochemistry; University of Buenos Aires; Buenos Aires Argentina
- Laboratory of Cellular and Molecular Biology; School of Medical Sciences; Institute for Biomedical Research (BIOMED CONICET-UCA); Pontifical Catholic University of Argentina (UCA); Buenos Aires Argentina
- National Research Council (CONICET); Buenos Aires Argentina
| | - DJ Martinel Lamas
- Radioisotopes Laboratory; School of Pharmacy and Biochemistry; University of Buenos Aires; Buenos Aires Argentina
- Laboratory of Cellular and Molecular Biology; School of Medical Sciences; Institute for Biomedical Research (BIOMED CONICET-UCA); Pontifical Catholic University of Argentina (UCA); Buenos Aires Argentina
| | - ES Rivera
- Radioisotopes Laboratory; School of Pharmacy and Biochemistry; University of Buenos Aires; Buenos Aires Argentina
| | - MA Garabalino
- Department of Radiobiology; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
| | - RO Farías
- Department of Technology and Applications of Accelerators; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
| | - SJ Gonzalez
- National Research Council (CONICET); Buenos Aires Argentina
- Department of Technology and Applications of Accelerators; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
| | - EM Heber
- Department of Radiobiology; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
| | - ME Itoiz
- Department of Radiobiology; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
- Department of Oral Pathology; Faculty of Dentistry; University of Buenos Aires; Buenos Aires Argentina
| | - RF Aromando
- Department of Oral Pathology; Faculty of Dentistry; University of Buenos Aires; Buenos Aires Argentina
| | - DW Nigg
- Idaho National Laboratory; Idaho Falls ID USA
| | - VA Trivillin
- Department of Radiobiology; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
- National Research Council (CONICET); Buenos Aires Argentina
| | - AE Schwint
- Department of Radiobiology; National Atomic Energy Commission; San Martin Province Buenos Aires Argentina
- National Research Council (CONICET); Buenos Aires Argentina
| |
Collapse
|
15
|
Molinari AJ, Thorp SI, Portu AM, Saint Martin G, Pozzi ECC, Heber EM, Bortolussi S, Itoiz ME, Aromando RF, Monti Hughes A, Garabalino MA, Altieri S, Trivillin VA, Schwint AE. Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels. Acta Oncol 2015; 54:99-106. [PMID: 24960584 DOI: 10.3109/0284186x.2014.925140] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (Seq-BNCT) in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48 hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization. MATERIAL AND METHODS Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization, followed by Seq-BNCT (Th+ Seq-BNCT) or Seq-Beam Only (Th+ Seq-BO) in the window of normalization. Boron microdistribution was assessed by neutron autoradiography. RESULTS Th+ Seq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between tumors pre-treated and not pre-treated with thalidomide were observed. CONCLUSION Th+ Seq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in tumor boron microdistribution is associated to an improvement in tumor control.
Collapse
Affiliation(s)
- Ana J Molinari
- Department of Radiobiology, National Atomic Energy Commission (CNEA) , San Martin, Province Buenos Aires , Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Trivillin VA, Abramson DB, Bumaguin GE, Bruno LJ, Garabalino MA, Monti Hughes A, Heber EM, Feldman S, Schwint AE. Boron neutron capture synovectomy (BNCS) as a potential therapy for rheumatoid arthritis: boron biodistribution study in a model of antigen-induced arthritis in rabbits. Radiat Environ Biophys 2014; 53:635-643. [PMID: 25156017 DOI: 10.1007/s00411-014-0564-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 08/14/2014] [Indexed: 06/03/2023]
Abstract
Boron neutron capture synovectomy (BNCS) is explored for the treatment of rheumatoid arthritis (RA). The aim of the present study was to perform boron biodistribution studies in a model of antigen-induced arthritis (AIA) in female New Zealand rabbits, with the boron carriers boronophenylalanine (BPA) and sodium decahydrodecaborate (GB-10) to assess the potential feasibility of BNCS for RA. Rabbits in chronic phase of AIA were used for biodistribution studies employing the following protocols: intra-articular (ia) (a) BPA-f 0.14 M (0.7 mg (10)B), (b) GB-10 (5 mg (10)B), (c) GB-10 (50 mg (10)B) and intravenous (iv), (d) BPA-f 0.14 M (15.5 mg (10)B/kg), (e) GB-10 (50 mg (10)B/kg), and (f) BPA-f (15.5 mg (10)B/kg) + GB-10 (50 mg (10)B/kg). At different post-administration times (13-85 min for ia and 3 h for iv), samples of blood, pathological synovium (target tissue), cartilage, tendon, muscle, and skin were taken for boron measurement by inductively coupled plasma mass spectrometry. The intra-articular administration protocols at <40 min post-administration both for BPA-f and GB-10, and intravenous administration protocols for GB-10 and [GB-10 + BPA-f] exhibited therapeutically useful boron concentrations (>20 ppm) in the pathological synovium. Dosimetric estimations suggest that BNCS would be able to achieve a therapeutically useful dose in pathological synovium without exceeding the radiotolerance of normal tissues in the treatment volume, employing boron carriers approved for use in humans. Radiobiological in vivo studies will be necessary to determine the actual therapeutic efficacy of BNCS to treat RA in an experimental model.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martin, Provincia de Buenos Aires, Argentina,
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Razetti A, Farías RO, Thorp SI, Trivillin VA, Pozzi ECC, Curotto P, Schwint AE, González SJ. Design, construction and application of a neutron shield for the treatment of diffuse lung metastases in rats using BNCT. Appl Radiat Isot 2014; 88:50-4. [PMID: 24447934 DOI: 10.1016/j.apradiso.2013.12.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2012] [Revised: 12/17/2013] [Accepted: 12/21/2013] [Indexed: 11/17/2022]
Abstract
A model of multiple lung metastases in BDIX rats is under study at CNEA (Argentina) to evaluate the feasibility of BNCT for multiple, non-surgically resectable lung metastases. A practical shielding device that comfortably houses a rat, allowing delivery of a therapeutic, uniform dose in lungs while protecting the body from the neutron beam is presented. Based on the final design obtained by numerical simulations, the shield was constructed, experimentally characterized and recently used in the first in vivo experiment at RA-3.
Collapse
Affiliation(s)
- A Razetti
- Universidad Favaloro, FICEN, Av. Belgrano 1723 (1093), C.A.B.A., Buenos Aires, Argentina
| | - R O Farías
- Universidad Favaloro, FICEN, Av. Belgrano 1723 (1093), C.A.B.A., Buenos Aires, Argentina; CONICET, Av. Rivadavia 1917 (1033), C.A.B.A., Córdoba, Argentina; Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - S I Thorp
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - V A Trivillin
- CONICET, Av. Rivadavia 1917 (1033), C.A.B.A., Córdoba, Argentina; Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - E C C Pozzi
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - P Curotto
- Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - A E Schwint
- CONICET, Av. Rivadavia 1917 (1033), C.A.B.A., Córdoba, Argentina; Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina
| | - S J González
- CONICET, Av. Rivadavia 1917 (1033), C.A.B.A., Córdoba, Argentina; Comisión Nacional de Energía Atómica (CNEA), Av. Gral Paz 1499 (1650), Buenos Aires, Argentina.
| |
Collapse
|
18
|
Garabalino MA, Heber EM, Monti Hughes A, Pozzi ECC, Molinari AJ, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: combined administration of BSH and BPA. Appl Radiat Isot 2013; 88:64-8. [PMID: 24360859 DOI: 10.1016/j.apradiso.2013.11.118] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 11/27/2013] [Accepted: 11/28/2013] [Indexed: 11/18/2022]
Abstract
Sodium mercaptoundecahydro-closo-dodecaborate (BSH) is being investigated clinically for BNCT. We examined the biodistribution of BSH and BPA administered jointly in different proportions in the hamster cheek pouch oral cancer model. The 3 assayed protocols were non-toxic, and showed preferential tumor boron uptake versus precancerous and normal tissue and therapeutic tumor boron concentration values (70-85ppm). All 3 protocols warrant assessment in BNCT studies to contribute to the knowledge of (BSH+BPA)-BNCT radiobiology for head and neck cancer and optimize therapeutic efficacy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Verónica A Trivillin
- National Atomic Energy Commission (CNEA), Argentina; National Research Council (CONICET), Argentina
| | - Amanda E Schwint
- National Atomic Energy Commission (CNEA), Argentina; National Research Council (CONICET), Argentina.
| |
Collapse
|
19
|
Pozzi ECC, Trivillin VA, Colombo LL, Monti Hughes A, Thorp SI, Cardoso JE, Garabalino MA, Molinari AJ, Heber EM, Curotto P, Miller M, Itoiz ME, Aromando RF, Nigg DW, Schwint AE. Boron neutron capture therapy (BNCT) for liver metastasis in an experimental model: dose–response at five-week follow-up based on retrospective dose assessment in individual rats. Radiat Environ Biophys 2013; 52:481-491. [PMID: 24077963 DOI: 10.1007/s00411-013-0490-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 08/24/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. Employing an experimental model of liver metastases in rats, we recently demonstrated that BNCT mediated by boronophenylalanine (BPA-BNCT) at 13 Gy prescribed to tumor is therapeutically useful at 3-week follow-up. The aim of the present study was to evaluate dose–response at 5-week follow-up, based on retrospective dose assessment in individual rats. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT (n = 19), Beam only (n = 8) and Sham (n = 7) (matched manipulation, no treatment). For each rat, neutron flux was measured in situ and boron content was measured in a pre-irradiation blood sample for retrospective individual dose assessment. For statistical analysis (ANOVA), individual data for the BPA-BNCT group were pooled according to absorbed tumor dose, BPA-BNCT I: 4.5–8.9 Gy and BPA-BNCT II: 9.2–16 Gy. At 5 weeks post-irradiation, the tumor surface area post-treatment/pre-treatment ratio was 12.2 ± 6.6 for Sham, 7.8 ± 4.1 for Beam only, 4.4 ± 5.6 for BPA-BNCT I and 0.45 ± 0.20 for BPA-BNCT II; tumor nodule weight was 750 ± 480 mg for Sham, 960 ± 620 mg for Beam only, 380 ± 720 mg for BPA-BNCT I and 7.3 ± 5.9 mg for BPA-BNCT II. The BPA-BNCT II group exhibited statistically significant tumor control with no contributory liver toxicity. Potential threshold doses for tumor response and significant tumor control were established at 6.1 and 9.2 Gy, respectively.
Collapse
|
20
|
Garabalino MA, Heber EM, Monti Hughes A, González SJ, Molinari AJ, Pozzi ECC, Nievas S, Itoiz ME, Aromando RF, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model. Radiat Environ Biophys 2013; 52:351-361. [PMID: 23591915 DOI: 10.1007/s00411-013-0467-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 03/23/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) is based on selective accumulation of ¹⁰B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg ¹⁰B/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, B1650KNA, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Hughes AM, Pozzi ECC, Thorp S, Garabalino MA, Farías RO, González SJ, Heber EM, Itoiz ME, Aromando RF, Molinari AJ, Miller M, Nigg DW, Curotto P, Trivillin VA, Schwint AE. Boron neutron capture therapy for oral precancer: proof of principle in an experimental animal model. Oral Dis 2013; 19:789-95. [DOI: 10.1111/odi.12077] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Revised: 12/26/2012] [Accepted: 12/28/2012] [Indexed: 11/26/2022]
Affiliation(s)
- A Monti Hughes
- Department of Radiobiology; National Atomic Energy Commission (CNEA); San Martin; Argentina
| | | | - S Thorp
- Department of Technology and Applications of Accelerators; CNEA; Ezeiza; Argentina
| | - MA Garabalino
- Department of Radiobiology; National Atomic Energy Commission (CNEA); San Martin; Argentina
| | - RO Farías
- Department of Technology and Applications of Accelerators; CNEA; Ezeiza; Argentina
| | | | - EM Heber
- Department of Radiobiology; National Atomic Energy Commission (CNEA); San Martin; Argentina
| | | | | | - AJ Molinari
- Department of Radiobiology; National Atomic Energy Commission (CNEA); San Martin; Argentina
| | - M Miller
- Department of Technology and Applications of Accelerators; CNEA; Ezeiza; Argentina
| | - DW Nigg
- Idaho National Laboratory; Idaho Falls; ID; USA
| | - P Curotto
- Department of Research and Production Reactors; CNEA; Ezeiza; Argentina
| | | | | |
Collapse
|
22
|
Pozzi ECC, Cardoso JE, Colombo LL, Thorp S, Monti Hughes A, Molinari AJ, Garabalino MA, Heber EM, Miller M, Itoiz ME, Aromando RF, Nigg DW, Quintana J, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model. Radiat Environ Biophys 2012; 51:331-339. [PMID: 22544068 DOI: 10.1007/s00411-012-0419-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2012] [Accepted: 04/14/2012] [Indexed: 05/31/2023]
Abstract
Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT, boronophenylalanine (BPA) + neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA-BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks post-treatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA-BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mg fell significantly to 19 ± 16 mg for BPA-BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA-BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA-BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.
Collapse
Affiliation(s)
- Emiliano C C Pozzi
- Department Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Molinari AJ, Aromando RF, Itoiz ME, Garabalino MA, Monti Hughes A, Heber EM, Pozzi ECC, Nigg DW, Trivillin VA, Schwint AE. Blood vessel normalization in the hamster oral cancer model for experimental cancer therapy studies. Anticancer Res 2012; 32:2703-2709. [PMID: 22753729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Normalization of tumor blood vessels improves drug and oxygen delivery to cancer cells. The aim of this study was to develop a technique to normalize blood vessels in the hamster cheek pouch model of oral cancer. MATERIALS AND METHODS Tumor-bearing hamsters were treated with thalidomide and were compared with controls. RESULTS Twenty eight hours after treatment with thalidomide, the blood vessels of premalignant tissue observable in vivo became narrower and less tortuous than those of controls; Evans Blue Dye extravasation in tumor was significantly reduced (indicating a reduction in aberrant tumor vascular hyperpermeability that compromises blood flow), and tumor blood vessel morphology in histological sections, labeled for Factor VIII, revealed a significant reduction in compressive forces. These findings indicated blood vessel normalization with a window of 48 h. CONCLUSION The technique developed herein has rendered the hamster oral cancer model amenable to research, with the potential benefit of vascular normalization in head and neck cancer therapy.
Collapse
Affiliation(s)
- Ana J Molinari
- Department of Radiobiology, National Atomic Energy Commission, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Heber EM, Kueffer PJ, Lee MW, Hawthorne MF, Garabalino MA, Molinari AJ, Nigg DW, Bauer W, Hughes AM, Pozzi ECC, Trivillin VA, Schwint AE. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential. Radiat Environ Biophys 2012; 51:195-204. [PMID: 22271404 DOI: 10.1007/s00411-011-0399-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2011] [Accepted: 12/27/2011] [Indexed: 05/31/2023]
Abstract
Boron neutron capture therapy (BNCT) combines selective accumulation of (10)B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na(3) [ae-B(20)H(17)NH(3)], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Molinari AJ, Pozzi ECC, Hughes AM, Heber EM, Garabalino MA, Thorp SI, Miller M, Itoiz ME, Aromando RF, Nigg DW, Trivillin VA, Schwint AE. Tumor Blood Vessel “Normalization” Improves the Therapeutic Efficacy of Boron Neutron Capture Therapy (BNCT) in Experimental Oral Cancer. Radiat Res 2012; 177:59-68. [DOI: 10.1667/rr2729.1] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Monti Hughes A, Pozzi ECC, Heber EM, Thorp S, Miller M, Itoiz ME, Aromando RF, Molinari AJ, Garabalino MA, Nigg DW, Trivillin VA, Schwint AE. Boron Neutron Capture Therapy (BNCT) in an oral precancer model: therapeutic benefits and potential toxicity of a double application of BNCT with a six-week interval. Oral Oncol 2011; 47:1017-22. [PMID: 21840244 DOI: 10.1016/j.oraloncology.2011.07.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Revised: 07/15/2011] [Accepted: 07/19/2011] [Indexed: 11/19/2022]
Abstract
Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10+BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB-10+BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10+BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.
Collapse
|
27
|
Molinari AJ, Pozzi ECC, Hughes AM, Heber EM, Garabalino MA, Thorp SI, Miller M, Itoiz ME, Aromando RF, Nigg DW, Quintana J, Santa Cruz GA, Trivillin VA, Schwint AE. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model. Radiat Res 2011; 175:463-72. [DOI: 10.1667/rr2148.1] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
28
|
Garabalino MA, Monti Hughes A, Molinari AJ, Heber EM, Pozzi ECC, Cardoso JE, Colombo LL, Nievas S, Nigg DW, Aromando RF, Itoiz ME, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model. Radiat Environ Biophys 2011; 50:199-207. [PMID: 21132507 DOI: 10.1007/s00411-010-0345-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2010] [Accepted: 11/13/2010] [Indexed: 05/17/2023]
Abstract
We previously demonstrated the therapeutic efficacy of different boron neutron capture therapy (BNCT) protocols in an experimental model of oral cancer. BNCT is based on the selective accumulation of (10)B carriers in a tumor followed by neutron irradiation. Within the context of exploring the potential therapeutic efficacy of BNCT for the treatment of liver metastases, the aim of the present study was to perform boron biodistribution studies in an experimental model of liver metastases in rats. Different boron compounds and administration conditions were assayed to determine which administration protocols would potentially be therapeutically useful in in vivo BNCT studies at the RA-3 nuclear reactor. A total of 70 BDIX rats were inoculated in the liver with syngeneic colon cancer cells DHD/K12/TRb to induce the development of subcapsular tumor nodules. Fourteen days post-inoculation, the animals were used for biodistribution studies. We evaluated a total of 11 administration protocols for the boron compounds boronophenylalanine (BPA) and GB-10 (Na(2)(10)B(10)H(10)), alone or combined at different dose levels and employing different administration routes. Tumor, normal tissue, and blood samples were processed for boron measurement by atomic emission spectroscopy. Six protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue. Boron concentration values in tumor and normal tissues in the liver metastases model show it would be feasible to reach therapeutic BNCT doses in tumor without exceeding radiotolerance in normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Aromando RF, Trivillin VA, Heber EM, Pozzi E, Schwint AE, Itoiz ME. Early effect of boron neutron capture therapy mediated by boronophenylalanine (BPA–BNCT) on mast cells in premalignant tissue and tumors of the hamster cheek pouch. Oral Oncol 2010; 46:355-9. [DOI: 10.1016/j.oraloncology.2010.02.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2010] [Revised: 02/11/2010] [Accepted: 02/12/2010] [Indexed: 10/19/2022]
|
30
|
Heber EM, Hughes AM, Pozzi EC, Itoiz ME, Aromando RF, Molinari AJ, Garabalino MA, Nigg DW, Trivillin VA, Schwint AE. Development of a model of tissue with potentially malignant disorders (PMD) in the hamster cheek pouch to explore the long-term potential therapeutic and/or toxic effects of different therapeutic modalities. Arch Oral Biol 2010; 55:46-51. [DOI: 10.1016/j.archoralbio.2009.10.010] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Revised: 09/28/2009] [Accepted: 10/26/2009] [Indexed: 11/25/2022]
|
31
|
Monti Hughes A, Heber EM, Pozzi E, Nigg DW, Calzetta O, Blaumann H, Longhino J, Nievas SI, Aromando RF, Itoiz ME, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT. Appl Radiat Isot 2009; 67:S313-7. [PMID: 19376711 DOI: 10.1016/j.apradiso.2009.03.070] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.
Collapse
Affiliation(s)
- A Monti Hughes
- Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Aromando RF, Heber EM, Trivillin VA, Nigg DW, Schwint AE, Itoiz ME. Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model. J Oral Pathol Med 2009; 38:448-54. [PMID: 19141057 DOI: 10.1111/j.1600-0714.2008.00720.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The therapeutic success of different boron neutron capture therapy (BNCT) protocols employing the hamster cheek pouch oral cancer model has been previously reported by our laboratory. The aim of this study was to explore potential mechanisms of BNCT-induced damage to tumor in terms of potential inhibition in DNA synthesis and induction of apoptosis in the tumors that underwent partial remission following application of the different BNCT protocols in this model. MATERIALS AND METHODS We evaluated DNA synthesis employing incorporation of 5-bromo-2'-deoxyuridine as an end-point. Apoptosis was evaluated by immunohistochemistry employing the deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling technique and Bax and Bcl-2 labeling. These studies were performed in tumors that underwent partial remission 1-30 days post-BNCT mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) or (BPA + GB-10). RESULTS BNCT exerted a marked inhibitory effect on DNA synthesis in tumors for all the protocols under study. The inhibitory effect of BPA-BNCT occurred as soon as 1 day post-treatment (P < 0.001). Conversely, the effect of GB-10-BNCT became apparent 7-14 days after therapy (P < 0.001) and was sustained until killed at 30 days post-treatment (P < 0.001). (GB-10 + BPA)-BNCT exerted a rapid and persistent effect, conceivably because of the combined effect of BNCT mediated by both boron compounds. The apoptosis studies did not show differences between the pre-treatment group and any of the BNCT groups. CONCLUSIONS One of the mechanisms involved in BNCT-induced tumor control in our model would be an inhibitory effect on DNA synthesis. Apoptosis does not seem to have a significant role in BNCT-induced tumor control in our model.
Collapse
Affiliation(s)
- Romina F Aromando
- Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires, Argentina.
| | | | | | | | | | | |
Collapse
|
33
|
Trivillin VA, Heber EM, Rao M, Cantarelli MA, Itoiz ME, Nigg DW, Calzetta O, Blaumann H, Longhino J, Schwint AE. Boron neutron capture therapy (BNCT) for the treatment of spontaneous nasal planum squamous cell carcinoma in felines. Radiat Environ Biophys 2008; 47:147-155. [PMID: 17955256 DOI: 10.1007/s00411-007-0138-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2007] [Accepted: 10/04/2007] [Indexed: 05/25/2023]
Abstract
Recently, Boron neutron capture therapy (BNCT) was successfully applied to treat experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa, with no damage to normal tissue. It was also shown that treating spontaneous nasal planum SCC in terminal feline patients with low dose BNCT is safe and feasible. In an extension of this work, the present study aimed at evaluation of the response of tumor and dose-limiting normal tissues to potentially therapeutic BNCT doses. Biodistribution studies with (10)B-boronophenylalanine (BPA enriched in (10)B) as a (10)B carrier were performed on three felines that showed advanced nasal planum SCC without any standard therapeutic option. Following the biodistribution studies, BNCT mediated by (10)BPA was done using the thermalized epithermal neutron beam at the RA-6 Nuclear Reactor. Follow-up included clinical evaluation, assessment of macroscopic tumor and normal tissue response and biopsies for histopathological analysis. The treated animals did not show any apparent radiation-induced toxicity. All three animals exhibited partial tumor control and an improvement in clinical condition. Enhanced therapeutic efficacy was associated with a high (10)B content of the tumor and a small tumor size. BNCT is therefore believed to be potentially effective in the treatment of spontaneous SCC. However, improvement in targeting (10)B into all tumor cells and delivering a sufficient dose at a greater depth are still required for the treatment of deep-seated, large tumors. Future studies are needed to evaluate the potential efficacy of the dual mode cellular (e.g. BPA-BNCT) and vascular (e.g. GB-10-BNCT) targeting protocol in a preclinical scenario, employing combinations of (10)B compounds with different properties and complementary uptake mechanisms.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Heber EM, Aromando RF, Trivillin VA, Itoiz ME, Nigg DW, Kreimann EL, Schwint AE. Therapeutic effect of boron neutron capture therapy (BNCT) on field cancerized tissue: Inhibition of DNA synthesis and lag in the development of second primary tumors in precancerous tissue around treated tumors in DMBA-induced carcinogenesis in the hamster cheek pouch oral cancer model. Arch Oral Biol 2007; 52:273-9. [PMID: 17137553 DOI: 10.1016/j.archoralbio.2006.10.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 09/18/2006] [Accepted: 10/07/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVE We previously reported the therapeutic success of different BNCT protocols in the treatment of oral cancer, employing the hamster cheek pouch model. The aim of the present study was to evaluate the effect of these BNCT protocols on DNA synthesis in precancerous and normal tissue in this model and assess the potential lag in the development of second primary tumors in precancerous tissue. The data are relevant to potential control of field cancerized tissue and tolerance of normal tissue. MATERIALS AND METHODS We evaluated DNA synthesis in precancerous and normal pouch tissue 1-30 days post-BNCT mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) or (BPA+GB-10) employing incorporation of 5-bromo-2'-deoxyuridine as an end-point. The BNCT-induced potential lag in the development of second primary tumors from precancerous tissue was monitored. RESULTS A drastic, statistically significant reduction in DNA synthesis occurred in precancerous tissue as early as 1 day post-BNCT and was sustained at virtually all time-points until 30 days post-BNCT for all the protocols. The histological categories evaluated individually within precancerous tissue (dysplasia, hyperplasia and NUMF [no unusual microscopic features]) responded similarly. DNA synthesis in normal tissue treated with BNCT oscillated around the very low pre-treatment values. A BNCT-induced lag in the development of second primary tumors was observed. CONCLUSIONS BNCT induced a drastic fall in DNA synthesis in precancerous tissue that would be associated to the observed lag in the development of second primary tumors. The minimum variations in DNA synthesis in BNCT-treated normal tissue would correlate with the absence of normal tissue radiotoxicity. The present data would support the control of field-cancerized areas by BNCT.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA San Martín, Prov Buenos Aires, Argentina
| | | | | | | | | | | | | |
Collapse
|
35
|
Trivillin VA, Heber EM, Nigg DW, Itoiz ME, Calzetta O, Blaumann H, Longhino J, Schwint AE. Therapeutic Success of Boron Neutron Capture Therapy (BNCT) Mediated by a Chemically Non-selective Boron Agent in an Experimental Model of Oral Cancer: A New Paradigm in BNCT Radiobiology. Radiat Res 2006; 166:387-96. [PMID: 16881740 DOI: 10.1667/rr3592.1] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The hypothesis of boron neutron capture therapy (BNCT) research has been that the short-range, high-linear energy transfer radiation produced by the capture of thermal neutrons by (10)B will potentially control tumor and spare normal tissue only if the boron compound selectively targets tumor tissue within the treatment volume. In a previous in vivo study of low-dose BNCT mediated by GB-10 (Na(2)(10)B(10)H(10)) alone or combined with boronophenylalanine (BPA) in the hamster cheek pouch oral cancer model that was primarily designed to evaluate safety and feasibility, we showed therapeutic effects but no associated normal tissue radiotoxicity. In the present study, we evaluated the response of tumor, precancerous and normal tissue to high-dose BNCT mediated by GB-10 alone or combined with BPA. Despite the fact that GB-10 does not target hamster cheek pouch tumors selectively, GB-10-BNCT induced a 70% overall tumor response with no damage to normal tissue. (GB-10+BPA)-BNCT induced a 93% overall tumor response with no normal tissue radiotoxicity. Light microscope analysis showed that GB-10-BNCT selectively damages tumor blood vessels, sparing precancerous and normal tissue vessels. In this case, selective tumor lethality would thus result from selective blood vessel damage rather than from selective uptake of the boron compound.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission,San Martín, Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Heber EM, Trivillin VA, Nigg DW, Itoiz ME, Gonzalez BN, Rebagliati RJ, Batistoni D, Kreimann EL, Schwint AE. Homogeneous boron targeting of heterogeneous tumors for boron neutron capture therapy (BNCT): chemical analyses in the hamster cheek pouch oral cancer model. Arch Oral Biol 2006; 51:922-9. [PMID: 16696934 DOI: 10.1016/j.archoralbio.2006.03.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2005] [Revised: 03/14/2006] [Accepted: 03/27/2006] [Indexed: 11/27/2022]
Abstract
OBJECTIVE BNCT is a tumour cell targeted radiation therapy. Uniform targeting of heterogeneous tumours with therapeutically effective boron carriers would contribute to a therapeutic effect on all tumour cell populations and avoid radioresistant fractions. This remains an unresolved challenge. The aim of the present study was to evaluate the degree of variation in boron content delivered by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) and the combined administration of (BPA+GB-10) in different portions of tumour, precancerous tissue around tumour and normal pouch tissue in the hamster cheek pouch oral cancer model. MATERIALS AND METHODS Samples of different areas of tumour, precancerous tissue and normal pouch tissue were taken from tumour-bearing hamsters, 3h post-administration of i.p. BPA (15.5mg B/kg b.w.), or i.v. GB-10 (50mg B/kg b.w.), or 3h and 1.5h post-administration respectively of i.v. GB-10 (34.5mg B/b.w.) and sequential i.p. injections of BPA (total dose 31mg B/kg b.w.) given jointly. Boron content was evaluated by inductively coupled plasma optical emission spectroscopy (ICP-OES). The degree of homogeneity in boron targeting was assessed in terms of the coefficient of variation (V: [S.D./mean]x100) of boron values. Statistical analysis of the results was performed by one-way ANOVA and the least significant difference test. RESULTS GB-10 and GB-10 plus BPA achieved respectively a statistically significant 1.8- and 3.3-fold increase in targeting homogeneity over BPA. CONCLUSIONS The combined boron compound administration protocol contributes to homogeneous targeting of heterogeneous tumours and would be expected to increase therapeutic efficacy of BNCT.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, B1650KNA San Martin, Prov. Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Rao M, Trivillin VA, Heber EM, Cantarelli MDLA, Itoiz ME, Nigg DW, Rebagliati RJ, Batistoni D, Schwint AE. BNCT of 3 cases of spontaneous head and neck cancer in feline patients. Appl Radiat Isot 2005; 61:947-52. [PMID: 15308173 DOI: 10.1016/j.apradiso.2004.05.016] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Having demonstrated BPA-BNCT induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of the RA-1 Reactor within a preclinical context. The biodistribution studies showed that, in all three cases evaluated, BPA delivered absolute boron values to tumor in the range that proved therapeutically useful in the experimental model of SCC. BPA-BNCT studies showed no radiotoxic effects, partial tumor control in terms of impaired growth and partial necrosis, an improvement in clinical condition and prolonged survival beyond the terminal condition of the feline patients at the time of recruitment.
Collapse
Affiliation(s)
- Mónica Rao
- Veterinary Oncology Center, Avenida del Libertador 15013, (1642) Acassuso, Prov. Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Stoliar P, Kreiner AJ, Debray ME, Caraballo ME, Valda AA, Davidson J, Davidson M, Kesque JM, Somacal H, DiPaolo H, Burlon AA, Ozafrán MJ, Vázquez ME, Minsky D, Heber EM, Trivillin VA, Schwint AE. Microdistributions of prospective BNCT-compound CuTCPH in tissue sections with a heavy ion microbeam. Appl Radiat Isot 2004; 61:771-4. [PMID: 15308142 DOI: 10.1016/j.apradiso.2004.05.062] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Microdistributions of the prospective BNCT-compound CuTCPH, a carborane-containing tetraphenylporphyrin with one Cu atom in its molecular structure, have been obtained in tissue sections of different organs of tumor-bearing and normal Syrian hamsters injected with the boron compound by employing a heavy ion microbeam. High resolution X-ray spectroscopy following micro-PIXE (Particle Induced X-ray Emission with micrometer-sized beams) with a focused (16)O ion beam was used. Focusing was performed with a heavy-ion scanning high-precision magnetic quadrupole triplet microprobe. Squamous Cell Carcinomas were induced on the right Cheek Pouch of Syrian Hamsters (HCP), sampled, cryo-sectioned and freeze-dried. Two-dimensional maps of elemental concentration were obtained by scanning the beam over the samples. Very non-uniform Cu concentrations were found in all sections.
Collapse
Affiliation(s)
- P Stoliar
- Departamento de Física, Argentine Atomic Energy Commission, CNEA, Av. Gral. Paz 1499, CP 1650, Bienos Aires, Villa Martelli, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Trivillin VA, Heber EM, Itoiz ME, Nigg D, Calzetta O, Blaumann H, Longhino J, Schwint AE. Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer. Appl Radiat Isot 2004; 61:939-45. [PMID: 15308172 DOI: 10.1016/j.apradiso.2004.05.015] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We previously reported biodistribution and pharmacokinetic data for GB-10 (Na(2)(10)B(10)H(10)) and the combined administration of GB-10 and boronophenylalanine (BPA) as boron delivery agents for boron neutron capture therapy (BNCT) in the hamster cheek pouch oral cancer model. The aim of the present study was to assess, for the first time, the response of hamster cheek pouch tumors, precancerous tissue and normal tissue to BNCT mediated by GB-10 and BNCT mediated by GB-10 and BPA administered jointly using the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. GB-10 exerted 75.5% tumor control (partial+complete remission) with no damage to precancerous tissue around tumor or to normal tissue. Thus, GB-10 proved to be a therapeutically efficient boron agent in this model despite the fact that it is not taken up selectively by oral tumor tissue. GB-10 exerted a selective effect on tumor blood vessels leading to significant tumor control with a sparing effect on normal tissue. BNCT mediated by the combined administration of GB-10 and BPA resulted in a reduction in the dose to normal tissue and would thus allow for significant escalation of dose to tumor without exceeding normal tissue tolerance.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission, Avenida General Paz 1499, (1650) San Martín, Provincia de Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Heber E, Trivillin VA, Nigg D, Kreimann EL, Itoiz ME, Rebagliati RJ, Batistoni D, Schwint AE. Biodistribution of GB-10 (Na(2)(10)B10H10 compound for boron neutron capture therapy (BNCT) in an experimental model of oral cancer in the hamster cheek pouch. Arch Oral Biol 2004; 49:313-24. [PMID: 15003550 DOI: 10.1016/j.archoralbio.2003.10.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/23/2003] [Indexed: 11/23/2022]
Abstract
OBJECTIVE We previously proposed the hamster cheek pouch model of oral cancer for BNCT studies. We herein present the biodistribution of a non-toxic boron compound, GB-10 (Na(2)(10)B10H10), in this model to assess its potential for BNCT or BNCT enhanced Fast Neutron Therapy. MATERIALS AND METHODS We evaluated the uptake and retention of GB-10 in tumour and precancerous tissue and in potentially dose-limiting, clinically relevant normal tissues. RESULTS Mean tumour boron concentration delivered by GB-10 (50mgB/kg) peaked to 77.7+/-28.0 ppm at 20min post-administration and remained at therapeutically useful values of 31.9+/-21.4 ppm at 3h. The clearance rate for normal tissues was faster than for tumour tissue. The consistently low brain and spinal cord values would preclude normal tissue toxicity. The uptake of GB-10 by precancerous tissue may be of potential use in the treatment of field cancerized areas. GB-10 was deposited homogeneously in different tumour areas, an asset when treating heterogenous tumours. The data suggests that the joint administration of BPA and GB-10 may improve the therapeutic efficacy of BNCT. CONCLUSIONS GB-10 is a potential boron carrier for BNCT of head and neck tumours and for BNCT-FNT.
Collapse
Affiliation(s)
- Elisa Heber
- Department of Radiobiology, National Atomic Energy Commission, Avenida del Libertador 8250, 1429 Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|